Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

<strong>Background</strong> We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. <br> <strong>Methods and findings</strong> I...

Full description

Bibliographic Details
Main Authors: Barry, H, Mutua, G, Kibuuka, H, Anywaine, Z, Sirima, SB, Meda, N, Anzala, O, Eholie, S, Bétard, C, Richert, L, Lacabaratz, C, McElrath, MJ, de Rosa, S, Cohen, KW, Shukarev, G, Robinson, C, Gaddah, A, Heerwegh, D, Bockstal, V, Luhn, K, Leyssen, M, Douoguih, M, Thiébaut, R, Thiebaut, R
Other Authors: EBL2002 Study group
Format: Journal article
Language:English
Published: Public Library of Science 2021

Similar Items